ONC101

ONC101 is an investigational drug developed by OncoInnovate. It is a small molecule designed to target cancer cells. The primary mechanism of action for ONC101 is believed to involve the disruption of tumor necrosis factor receptor 1 (TNFR1) signaling pathways. This pathway is known to play a role in inflammation and cell death, and its aberrant activation has been observed in various cancers.

Research into ONC101 has focused on its potential therapeutic effects in several types of cancer, including glioblastoma and other solid tumors. Preclinical studies have suggested that ONC101 can induce tumor cell death and inhibit tumor growth. Clinical trials have been initiated to evaluate the safety and efficacy of ONC101 in human patients. These trials are exploring different dosages and administration routes, as well as combinations with other cancer therapies. The development of ONC101 is ongoing, and further data from clinical trials are needed to determine its ultimate role in cancer treatment. The drug is not currently approved by regulatory agencies for any indication.